secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001104659-25-097561
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia closes $88M sale of BioEnvelope business to Boston Scientific; pivots to NXT-41x
--------------------------------------------------------------------------------

- Closed sale of CIED/BioEnvelope business to Boston Scientific for $88M cash; $80.3M paid at closing, $8M escrowed for 12 months.
- Used $27.8M of proceeds to fully repay and terminate SWK Credit Agreement (principal $24.5M plus fees).
- Amended Ligand royalty agreement: paid $1.1M accrued royalties; Ligand consented to sale and released security interest in CIED assets.
- Company will focus on NXT-41x drug-eluting biomatrix for breast reconstruction; expects launch first half 2027.
- Pro forma cash balance ~$57M; Device Protection Business reported as discontinued operations in future filings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925097561/0001104659-25-097561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925097561/tm2528122d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-097561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer